CDK9-IN-40

CDK9-IN-40 is a potent and orally active CDK9 inhibitor with an IC50 of 5.5 nM. CDK9-IN-40 shows high selectivity for CDK9 versus CDK1, CDK2, CDK4, and CDK6, respectively. CDK9-IN-40 can arrest cell cycle, induce cell apoptosis and inhibit tumor growth. CDK9-IN-40 exhibits strong anti-cancer activity[1].

Product Specifications

UNSPSC

12352005

Target

Apoptosis; CDK

Related Pathways

Apoptosis; Cell Cycle/DNA Damage

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Smiles

CN1CCN(CC1)C2=CC=C(C=C2)NC3=NC(N4CCC5=C(SC(N)=N5)C4)=CC=N3

Molecular Formula

C21H26N8S

Molecular Weight

422.55

References & Citations

[1]Chen L et al. Discovery and optimization of novel tetrahydrothiazolopyridine-based pyrimidines as highly potent cyclin-dependent kinase 9 (CDK9) inhibitors. Eur J Med Chem. 2025 Jun 14;296:117875. doi: 10.1016. https://pubmed.ncbi.nlm.nih.gov/40544651/|[2]Chen L et al. Discovery and optimization of novel tetrahydrothiazolopyridine-based pyrimidines as highly potent cyclin-dependent kinase 9 (CDK9) inhibitors. Eur J Med Chem. 2025 Jun 14;296:117875. doi: 10.1016.